Although the harms of screening for prostate cancer with the prostate-specific antigen (PSA) test outweigh the benefits, 560,000 Ontario men undergo PSA screening each year. Guideline developers, such as the Canadian Task Force on Preventive Health Care (CTFPHC), have disseminated patient educational materials (PEMs) on PSA screening widely in Ontario, yet men remain confused about screening harms and benefits. One potential contributing factor may be that PEMs are typically developed by researchers and clinicians and may not address patient barriers to change. The investigators will assess whether a PSA screening PEM that is co-created with patients provides added value over PEMs developed using the traditional approach (i.e., researchers and clinicians develop a PEM with patient involvement in usability testing only. The investigators will also assess satisfaction with the engagement process and calculate the costs and resources required for each method (i.e. co-creation, usability, and recommendations only). This study will generate a PSA screening PEM to help patients make evidence-based screening decisions. It will also help Ontario organizations, including Cancer Care Ontario, identify optimal methods for developing PEMs for PSA screening and other areas of preventive health care, such as breast and colorectal cancer screening.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Enrollment
573
A co-created PEM has been designed in collaboration with patients.
St. Michael's Hospital
Toronto, Ontario, Canada
Pretest-posttest change in prostate cancer screening decisional conflict and intention to be screened between the co-created PEM group and the traditional PEM group.
The investigators will assess differences and changes in prostate cancer screening decisional conflict and intention to be screened for the co-created PEM group and the traditional PEM group using repeated measures ANOVAs.
Time frame: This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.
Pretest-posttest change in knowledge of prostate cancer screening
The investigators will assess the differences in the pretest-posttest change in prostate cancer screening knowledge between the co-created PEM group and the traditional PEM group using a 7-item knowledge measure. Assessed by conducting a repeated measures analysis of variance (ANOVA).
Time frame: This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.
Comparison of PEM usability
The investigators will assess the differences between the two study arms in PEM/recommendation usability using a one-way ANOVA
Time frame: This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month.
Participant preference of PEM
The investigators will evaluate participants' preferred material (co-created or traditional PEM). Use a chi-square test to analyze the difference in the proportion of patients who prefer each type of material.
Time frame: This measure will be assessed from date of randomization until date of survey completion, assessed up to 1 month
Resources use for PEM development
The investigators will record the resources required (e.g., personnel hours and participant reimbursement) for a health care organization to develop a co-created PEM in comparison to a PEM created by clinicians and researchers.
Time frame: This measure will be assessed after the intervention (survey) is administered (i.e., post analysis), up to 1 month.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.